TauRx Pharmaceuticals
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Liberty Building Foresterhill Rd, Aberde...Phone Number
+44 1224555709Website
www.taurx.comRevenue
$27.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About TauRx Pharmaceuticals
TauRx Pharmaceuticals, founded in 2002 and headquartered in Aberdeen, UK, is a clinical-stage pharmaceutical company. The Company develops drugs to treat Alzheimer's disease and other neurodegenerative disorders.Explore more
TauRx Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TauRx Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once TauRx Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at TauRx Pharmaceuticals
Website visits: Recent activity has been detected on your website
Check if TauRx Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when TauRx Pharmaceuticals launches new products
Earning: See what the market has to say on TauRx Pharmaceuticals recently announced quarterly report
TauRx Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if TauRx Pharmaceuticals is spiking on competitors!
Click to see if TauRx Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to TauRx Pharmaceuticals
Compare insights from companies similar to TauRx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TauRx Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
TauRx Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about TauRx Pharmaceuticals.
TauRx Pharmaceuticals financials insights
Gather financial insights about TauRx Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Unspecified
$31.5M
Other Financing Round
$112M
2013
Debt
$10.5M
2015
Private Equity
$135M
2022
Other Financing Round
$119M
TauRx Pharmaceuticals Tech Stack
A closer look at the technologies used by TauRx Pharmaceuticals
See more technologies
TauRx Pharmaceuticals News & Media
Dundee Corporation Announces the Sale of 8,000 Shares of TauRx Pharmaceuticals Ltd. for Proceeds of US$1 Million
TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the “Company” or “Dundee”) announced today that it has sold to a private investor 8,000 of the 1,015,008 shares it holds in TauRX Pharmaceuticals Ltd. (“TauRx”) at a price of US$125 per share for proceeds to the Company of US$1,000,000. The transaction remains subject to TauRx board approval. Following the completion of the transaction Dundee will continue to hold 1,007,008 TauRx shares.TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
ABERDEEN, Scotland--(BUSINESS WIRE)--TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM) for treatment of mild cognitive impairment (MCI-AD) and mild to moderate stages of dementia due to Alzheimer’s disease. HMTM has been designated by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the Innovative Licensing andTwo Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial
ABERDEEN, Scotland--(BUSINESS WIRE)--TauRx presents 24-month data from Phase 3 LUCIDITY trial of HMTM showing sustained benefits across disease spectrum from early to moderate dementia.TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March
ABERDEEN, Scotland--(BUSINESS WIRE)--TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal. Professor Claude Wischik, Co-Founder, CEO and Executive Chairman of TauRx will present data including details
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TauRx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
TauRx Pharmaceuticals, founded in 2002 and headquartered in Aberdeen, UK, is a clinical-stage pharmaceutical company. The Company develops drugs to treat Alzheimer's disease and other neurodegenerative disorders.... Read More
